How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?

Ashley Pinchinat; Elizabeth Raetz

doi:10.3324/haematol.2021.280395

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?

Research output: Contribution to journal › Editorial

1 Scopus citations

Original language	English
Pages (from-to)	2292-2294
Number of pages	3
Journal	Haematologica
Volume	107
Issue number	10
DOIs	https://doi.org/10.3324/haematol.2021.280395
State	Published - Oct 2022
Externally published	Yes

Access to Document

10.3324/haematol.2021.280395

Cite this

@article{6609b4f60b164be6a7d90da362746e3c,

title = "How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?",

author = "Ashley Pinchinat and Elizabeth Raetz",

note = "Funding Information: ER receives institutional research funding from Pfizer and serves on a Data and Safety Monitoring Board for Celgene/BMS.",

year = "2022",

month = oct,

doi = "10.3324/haematol.2021.280395",

language = "English",

volume = "107",

pages = "2292--2294",

journal = "Haematologica",

issn = "0390-6078",